Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

Bioverativ

- PMLiVE

The fight for affordable insulin

Activists are organised, and demanding action on US insulin prices - and pointing the finger at pharma

- PMLiVE

Tecfidera successor’s side-effect profile boosts Biogen

But analysts unconvinced that patients will switch

- PMLiVE

Dupixent drives Sanofi again, but other new drugs are lagging

Reported loss due to restructuring

- PMLiVE

Biogen grows in Q2, but Spinraza performance a concern

Company banking on pipeline readouts and Tecfidra defence

- PMLiVE

FDA verdict on Sanofi’s Darzalex rival is due in April 2020

One of several anti-CD38 antibodies in pipeline

- PMLiVE

M&F Health, 90TEN and Sanofi among big winners at Communiqué Awards

Full results from health comms awards

- PMLiVE

NICE backs CDF funding for Sanofi/Regeneron’s skin cancer drug Libtayo

Acknowledges unmet need

- PMLiVE

Biogen bounces back with Spinraza early treatment data

Takes battle to Novartis in youngest patients

- PMLiVE

Sanofi/Regeneron’s IO latecomer Libtayo approved in Europe

Licensed to treat one of the most commonly diagnosed skin cancers

- PMLiVE

Rivals rise as safety issue mars Pfizer’s DMD gene therapy trial

Company to press ahead with phase 3 trial

- PMLiVE

Alexion’s Soliris adds new approval in rare disease NMOSD

First ever drug approved for rare autoimmune disease

- PMLiVE

FDA clears Dupixent as first-ever drug for chronic rhinosinusitis with nasal polyps

Could add $1bn to revenues, say analysts

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links